Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc. (IDYA)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: IDEAYA is a precision medicine oncology company focused on discovering and developing transformative therapies for cancer, specifically targeting molecularly defined solid tumors. The company has no approved products and generates revenue solely through collaboration agreements.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 | Q4 2025 |
|---|---|---|---|
| Total Revenue | $6.6 million | $0 | $10.9 million |
| Net Loss | $(98.5) million | $(72.2) million | $(83.3) million |
| Loss Per Share (Basic & Diluted) | $(1.11) | $(0.82) | N/A |
| Operating Expenses | $115.1 million | $84.4 million | $105.4 million |
| Research & Development (R&D) | $95.7 million | $70.9 million | $86.6 million |
| General & Administrative (G&A) | $19.4 million | $13.5 million | $18.8 million |
| Cash, Cash Equivalents & Marketable Securities | $972.9 million | N/A | $1,049.7 million |
| Net Cash Used in Operating Activities | $(75.2) million | $(60.3) million | N/A |
| Accumulated Deficit | $(835.1) million | N/A | $(736.5) million |
Material Changes vs. Prior Periods
- Revenue Recognition: The company recognized $6.6 million in collaboration revenue in Q1 2026, primarily from the Servier License Agreement. This represents a new revenue stream compared to Q1 2025, where no revenue was recognized. However, revenue decreased 40% sequentially from Q4 2025 ($10.9 million) due to the timing of performance obligation satisfaction.
- Expense Growth: Total operating expenses increased 36% year-over-year (Q1 2026 vs. Q1 2025). R&D expenses rose 35% to $95.7 million, driven by increased fees to CROs/consultants ($19.5 million increase) and personnel costs ($4.3 million increase) to advance clinical programs.
- Net Loss Expansion: Net loss widened by 37% year-over-year to $98.5 million, reflecting the significant increase in operating costs outpacing the new collaboration revenue.
- Liquidity Position: Total cash and marketable securities decreased from $1.05 billion at year-end 2025 to $972.9 million at March 31, 2026, primarily due to operating cash burn, partially offset by net cash provided by investing activities ($119.0 million) from the maturity of marketable securities.
Guidance, Outlook, and Strategic Updates
- Clinical Milestones:
- Darovasertib (PKC): Reported positive topline data in April 2026 from the OptimUM-02 Phase 2/3 trial for metastatic uveal melanoma, showing statistically significant improvements in progression-free survival and overall survival. Plans to submit a New Drug Application (NDA) in H2 2026.
- IDE849 (DLL3 ADC): Initiated global Phase 1/2 trials; Hengrui Pharma partner targeting Phase 3 initiation in China in 2027.
- IDE034 (B7H3/PTK7 ADC): Initiated Phase 1 dose escalation in Q1 2026, triggering a $5.0 million milestone payment to Biocytogen.
- Strategic Partnerships & Terminations:
- Servier: Entered an exclusive license agreement in August 2025 for darovasertib outside the U.S., receiving a $210 million upfront payment and eligible for up to $320 million in milestones.
- GSK Termination: GSK notified the company in December 2025 of its intention to terminate the collaboration agreement, effective March 9, 2026. IDEAYA plans to discontinue development of IDE705 (Pol Theta) and IDE275 (Werner Helicase) and is evaluating strategic options for these assets.
- Gilead Deprioritization: In March 2026, the company deprioritized clinical activity with Gilead evaluating the combination of IDE397 and Trodelvy to focus on proprietary MTAP-deleted pipeline assets.
- Liquidity Outlook: Management believes current cash, cash equivalents, and marketable securities ($972.9 million) are sufficient to fund planned operations for at least 12 months from the filing date (May 5, 2026).
- Risks: The company faces risks related to the success of clinical trials, regulatory approvals, the ability to raise additional capital, and the integration of assets following the GSK termination.
Investor Verification Checklist
- Revenue Sustainability: Verify the timing and magnitude of future revenue recognition from the Servier agreement, specifically the $155.3 million in remaining performance obligations.
- Cash Burn Rate: Monitor the quarterly net cash used in operating activities ($75.2 million in Q1) against the $972.9 million cash balance to assess runway duration.
- Clinical Data Validation: Review the full data presentation from the OptimUM-02 trial at the ASCO 2026 meeting to confirm the statistical significance of the topline results.
- Asset Strategy Post-GSK: Assess the strategic options and potential value recovery for the IDE705 and IDE275 programs following the GSK collaboration termination.
- Capital Requirements: Evaluate the need for future financing given the accumulated deficit of $835.1 million and the lack of product sales revenue.